Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

Incretin peptides, principally GLP-1 and GIP, regulate islet hormone secretion, glucose
concentrations, lipid metabolism, gut motility, appetite and body weight, and immune …

Background Many antihyperglycaemic drugs, including insulin, are primarily cleared by the
kidneys, restricting treatment options for patients with kidney disease. Dulaglutide is a long …

The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM) are common
conditions that regularly co-exist and can act synergistically to drive adverse outcomes. The …

Abstract Glucagon-like peptide-1 (GLP-1) is produced in gut endocrine cells and in the
brain, and acts through hormonal and neural pathways to regulate islet function, satiety, and …

Glucagon-like peptide 1 (GLP-1) analogs are increasingly being used in the treatment of
type 2 diabetes. It is clear that these drugs lower blood glucose through an increase in …

Abstract Glucagon-like peptide-1 (GLP-1) controls islet hormone secretion, gut motility, and
body weight, supporting development of GLP-1 receptor agonists (GLP-1RA) for the …

Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the two major
types of chronic liver disease worldwide. Inflammatory processes play key roles in the …